Quinoxaline-Based Monoamine Oxidase Inhibitors: Design Strategies, Synthesis, Structure-Activity Relationships, and Therapeutic Potential in Neurological Disorders: A Review From 1996 to 2026.
Level 5 - mechanism / opinion, no new human data
Narrative review of medicinal chemistry and preclinical structure-activity relationship literature with no new human data.
PubMed 42410707 · doi:10.1002/cmdc.70330
What was done
The authors conducted a narrative literature review spanning 1996 to 2026 summarizing rational design strategies, chemical synthesis, structure-activity relationships, and pharmacological properties of quinoxaline-based monoamine oxidase (MAO-A and MAO-B) inhibitors for neurological disorders.
What was found
The abstract reports no quantitative values, binding affinities, or effect sizes. It qualitatively reports that substituent choices and positional modifications on the quinoxaline core influence MAO-A versus MAO-B selectivity, metabolic stability, and blood-brain barrier permeability.
Why it matters
It organizes medicinal chemistry principles to assist in the rational design and structural optimization of brain-penetrant MAO inhibitors targeting neurological conditions.
Limits
The paper is a narrative review focused on preclinical and biochemical literature without human clinical data. The abstract provides no quantitative synthesis, search protocol details, or study counts.
Cited by
- supports MAOA is an enzyme that degrades monoamines which regulate neuronal communication.